Abstract: Peritoneal protein clearance (PPCl) depends upon vascular supply and size selective permeability. Some previous reports suggested PPCl can distinguish fast peritoneal membrane transport due to local or systemic inflammation. However, as studies have been discordant, we wished to determine factors associated with an increased PPCl. Consecutive patients starting peritoneal dialysis (PD) who were peritonitis-free were studied. Data included a baseline peritoneal equilibration test (PET), measurement of dialysis adequacy, 24-h dialysate PPCl and body composition measured by multifrequency bioimpedance. 411 patients, mean age 57.2 AE 16.6 years, 60.8% male, 39.4% diabetic, 20.2% treated by continuous ambulatory peritoneal dialysis (CAPD) were studied. Mean PET 4-h Dialysate/Serum creatinine was 0.73 AE 0.13, with daily peritoneal protein loss 4.6 (3.3-6.4) g, and median PPCl 69.6 (49.1-99.6) mL/day. On multivariate analysis, PPCl was most strongly associated with CAPD (β 0.25, P < 0.001), extracellular water (ECW)/total body water (TBW) ratio (β 0.21, P < 0.001), skeletal muscle mass index (β 0.21, P < 0.001), log N-terminal brain natriuretic peptide (NT-proBNP) (β 0.17, P = 0.001), faster PET transport (β 0.15, P = 0.005), and normalized nitrogen appearance rate (β 0.13, P = 0.008). In addition to the longer dwell times of CAPD, greater peritoneal creatinine clearance and faster PET transporter status, we observed an association between increased PPCl and ECW expansion, increased NT-proBNP, estimated dietary protein intake and muscle mass, suggesting a link to sodium intake and sodium balance, increasing both ECW and conduit artery hydrostatic pressure resulting in greater vascular protein permeability. This latter association may explain reports linking PPCl to patient mortality.
An increasing number of patients with chronic kidney disease are treated with peritoneal dialysis (PD) world-wide. After peritonitis (1), failure to prevent extracellular volume expansion (2) is a common cause of patients changing dialysis modality to hemodialysis. Earlier observational studies suggested an association between faster peritoneal transporter status and increased risk for both PD treatment failure and patient mortality (3) . However, later observational studies, including patients treated with automated peritoneal dialysis cyclers (APD) and icodextrin, reported no differences in patient outcomes (4) or extracellular water (ECW) hydration (5) with transporter status.
Peritoneal transporter status depends upon the blood supply to the abdominal cavity. Faster peritoneal transport is associated with greater capillary surface area, which can be found physiologically with larger body size, or pathologically due to local or systemic inflammation (6) . Peritoneal protein clearance (PPCl), has been proposed to separate faster transport status due to inflammatory conditions, as protein clearance is a measure of large pore flow and is predominantly dependent upon large pore numbers, which are reported to increase with inflammation (6) . As such, an increased PPCl has been suggested to be a marker for increased vascular permeability, and several studies reported an association between increased PPCl with hypoalbuminemia, PD failure and increased mortality in PD patients (7) (8) (9) . However, not all studies demonstrated an association of increased PPCl and mortality (10) .
In view of the discrepancy of these reports, and differences between studies as to whether PPCl was affected by patient body size, peritoneal transport status, age, various co-morbid conditions, pulse pressure, C-reactive protein (CRP) and urine output (7) (8) (9) (10) (11) (12) , we reviewed PPCl at the time of first peritoneal membrane assessment in a cohort of patients starting PD.
PATIENTS AND METHODS
We compared 4-h peritoneal dialysate effluent creatinine and total protein to corresponding serum samples (S) when PD patients attended for their first routine outpatient peritoneal equilibrium testing (PET) using a standard 22.7 g/L dextrose exchange (13) . All patients using 7.5% icodextrin, had icodextrin drained and a glucose exchange instilled prior to PET. Dialysate (D) creatinine was measured using a kinetic enzymatic method to prevent glucose interference (P module analyzer, Roche Integra, Roche Diagnostics, Lewes, UK) (14) . Serum and dialysate total protein were measured by a modified biuret method (colorimetric assay based on divalent copper reacting in alkaline solution with protein peptide bonds to form a characteristic purple-colored biuret complex, measuring increased absorbance at 546 nm), and peritoneal dialysate protein using pyrogallol red which complexes with proteins in an acid environment containing molybdate ions, and measuring absorbance at 600 nm. This method is linear at lower protein concentrations, but higher concentration samples above 1.25 g/L were diluted to bring them into range (8) . Serum albumin was measured by bromcresol green method, and N terminal brain natriuretic peptide (NT-proBNP) (P module analyzer, Roche Integra, Roche Diagnostics). C-reactive protein (CRP) was measured using the same assay as the UK National Amlyoid center, with values reported to <1 mg/L (15, 16) , and hemoglobin by an automated counter (Sysmex XN900, Sysmex Corporation, Kobe, Japan) (17) . Multifrequency bioelectrical impedance assessments (MFBIA) were made using a standard protocol (InBody 720 Body Composition Analysis, Biospace, Seoul, South Korea), with the dialysate drained out at the end of the PET (18, 19) . Extracellular water volume (ECW) excess was expressed as the ratio of ECW to total body water (TBW).
Data were available from 411 consecutive adult PD patients attending for their first peritoneal membrane assessment (13) , with corresponding MFBIA measurements. Patients with pacemakers and amputees were excluded from MFBIA. We also excluded patients who had had a previous episode of peritonitis. These were routine tests performed on stable outpatients, at least 6 weeks after any hospital admission. Patient co-morbidity was assessed using the Stoke-Davies grade (20) , and primary renal disease categorized as diabetic nephropathy, glomerular disease, tubular-interstitial disease, hypertensive diseases, and unknown. Patient peritoneal transporter status was determined by 4-h peritoneal to serum creatinine ratios (13) . Normalized nitrogen appearance rate (nPNA) was estimated using the Bergström equation (21), skeletal muscle mass by MFBIA (22) and indexed to height, and peritoneal and urinary clearances estimated by standard equations (13) . Peritoneal protein clearance was calculated as suggested by Haraldsson (23) , from 24-h total peritoneal protein losses and expressed as mL of plasma cleared per day (mL/day). Daily estimated sodium losses were calculated by the difference between peritoneal dialysate effluent and urinary sodium and sodium content of dialysate infilled.
Statistical analysis
Results are expressed as mean AE standard deviation, or median and interquartile range, or percentage. ANOVA or Kruskal-Wallis, with appropriate correction for multiple analyses were used to compare groups. Spearman's correlation was used for univariate analysis, and all variables with a statistical association of P < 0.1, and those thought to be of clinical significance (gender, PET transporter, primary renal disease, prescription of 7.5% icodextrin and 22.7 g/L dextrose, and anti-hypertensive medications), were used to create a multivariable model to determine associations with PPCl. Variables that were not significant and did not improve model fit, or demonstrated co-linearity or increased variable inflation factor, were excluded in a step backward model. If required, nonparametric variables were log transformed. Statistical analysis was performed using Graph Pad Prism (version 6.0, Graph Pad, San Diego, CA, USA, and SPSS version 24.0). Statistical significance was taken at or below the 5% level.
Our retrospective audit complied with NHS guidelines (UK NHS guidelines for clinical audit and service development, available at http://www.hra.nhs.uk/ documents/2013/09/defining-research.pdf, and http:// www.gov.uk/government/publications/health-researchethics-committees-governancearrangements). Individual consent was waived as all laboratory tests and MFBIA had been performed as part of the routine clinical care of kidney dialysis patients in keeping with the standard operating policy and no patient identifiable data was used.
RESULTS
We reviewed the records of 411 consecutive adult patients attending for their first assessment of peritoneal membrane function 2 (2-3) months after PD catheter insertion and training, mean age 57. Twenty percent were treated by continuous ambulatory peritoneal dialysis (CAPD), the remainder on cyclers with 25.8% on overnight cyclers with no daytime exchange (APD) and the remainder using a daytime exchange, continuous cycling peritoneal dialysis (CCPD) ( Table 1) . Patients treated by CAPD were older, with higher NT-proBNP, and greater ECW/TBW ratio and lower muscle mass (Table 1) . Those treated by APD without a daytime exchange had greater residual renal function, and urinary protein excretion was greater for those treated by CCPD. Serum total protein was similar between PD modalities. 24-h PD protein loss and PPCl were greater for the CAPD cohort. Although patients treated by APD had lower PET 4-h D/S creatinine ratios, the 4-h D/S total protein was higher.
We then determined whether primary renal disease had an effect on PPCl. Patients with glomerular disease were generally younger, and those with diabetic nephropathy greater ECW/TBW ratios, and NT-proBNP values were higher in those with diabetic nephropathy and hypertensive nephropathy ( Table 2) . Serum protein and PET results were not different between the groups. Residual renal function was similar, although urinary protein losses were greater for those with diabetic nephropathy and those with glomerular diseases. PPCl was lower in those patients with glomerular disease.
Comparing patients according to PET creatinine transporter status, the fast transporters had lower total serum protein, greater PET and 24-h protein losses, and greater PPCl (Table 3 ). More male patients were faster transporters than slow transporters, and faster transporters had greater muscle mass compared to slow transporters. ECW/TBW ratios were greatest for the faster transporters.
On univariate analysis serum total protein, NTproBNP, ECW/TBW, PET 4-h D/S creatinine, 24-h glucose absorption, serum albumin, age, StokeDavies co-morbidity, and pulse pressure were all highly associated with PPCl (P < 0.001) (Table S1 ). Peritoneal ultrafiltrate, prescription of 22.7% glucose and net daily sodium losses were also associated with PPCl (P < 0.01). We then chose variables which were associated with PPCl on univariate analysis and constructed a multivariable model to determine which factors were independently associated with PPCl (Table 4) . As expected faster PET transporter status and CAPD modality were associated with greater PPCl, as were skeletal muscle mass index and nPNA, and greater peritoneal creatinine clearance. However, PPCl was also associated with greater ECW/TBW ratios and NT-proBNP concentrations, and negatively with both serum total protein concentration and urinary protein loss.
DISCUSSION AND CONCLUSIONS
Peritoneal protein transport is much slower than that of creatinine, and as such the 4-h D/S total protein to creatinine ratios were around one hundred times lower. Peritoneal protein losses were greater with the longer CAPD dwell exchanges compared to APD cyclers without a daytime exchange, and PPCl was greater for those treated by CAPD compared to both APD and CCPD. Similarly, 4-h-PET protein losses and 24-h peritoneal protein losses and PPCl were greater for those patients classified as fast transporters. In addition, PCCL was greater for those with greater peritoneal creatinine clearance.
Previous reports have differed as to whether primary renal diseases have an effect on peritoneal protein excretion, with some suggesting increased protein excretion in those with diabetic nephropathy and diabetes (12, 24, 25) . We were unable to confirm this suggestion made in much smaller cohorts of patients. However, we did find that PPCl was lower in patients classified as having glomerular diseases as the primary cause of renal disease. These patients, and those with diabetic nephropathy, had the greatest urinary protein losses, and, on *P < 0.05, **P < 0.01, ***P < 0.001 vs. Diabetic nephropathy. Four hourly peritoneal equilibration test (PET) dialysate to serum ratio (4 h D/S), skeletal muscle mass (SMM), percentage ratio extracellular to total body water (%ECW/TBW), n terminal probrain natriuretic peptide (NT-proBNP). Results expressed as integer, percentage, mean AE standard deviation, median (interquartile range) or percentage. multivariable testing, greater urinary protein loss was associated with lower PPCl.
Reports suggested increased PPCl in older patients (7, 25) , although several other observational studies reported no effect of age (9, 26) . We noted a univariate association with patient age, but in our cohort more older patents were treated by CAPD, whereas younger and more active patients were treated by APD and CCPD. However, on multivariable testing, patient age was no longer a significant factor. PPCl could also be affected by the intraabdominal capillary surface area available for transport, and several studies have reported greater PPCl in male patients (9, 25, 27) , although others found no effect with gender (10,26). We did not note an effect of gender, but noted that patient size, as expressed by ICW, ECW, skeletal muscle mass and height, were all associated with PPCl on univariate analysis, but not weight, body mass index or body surface area. Previous authors have commented that although the intra-abdominal capillary surface area increases with body size, there is no simple relationship to weight, body mass index or body surface area (7) .
Previous reports have reported various associations between hypertension (25), and pulse pressure (9) , and PPCl, and in theory raised intravascular hydrostatic pressure could increase PPCl. On the other hand, others found no effect of blood pressure (27) . We noted a univariate association with pulse pressure, and systolic pressure, but not mean arterial blood pressure, or anti-hypertensive medications prescribed. There was also an association with sodium losses, and assuming patients were in a steady state, then this may be an estimate of sodium intake. Dietary sodium intake is often linked to protein intake (28) , and accumulation of sodium in tissues can lead to an increase in vascular stiffness (29) and pulse wave velocity (30) . A positive sodium balance would be expected to expand the ECW and increase cardiac natriuretic peptides. On multivariable analysis, PPCl was greater in those patients with greater dietary protein intake, muscle mass, and higher serum NT-proBNP and ECW/TBW ratios, which may suggest an association with greater sodium intake. Many previous observational studies have noted a relationship between PCCL and increasing comorbidity (9, 10, 12) . Although there was a strong univariate association between PPCl and StokeDavies co-morbidity grading, this was lost on multivariable analysis. However, we report an independent association between PPCl and both ECW/TBW and NTproBNP. Increased ECW and NT-proBNP are increased in cases of volume overload in peritoneal dialysis patients (31, 32) , but ECW/TBW and NT-proBNP can also be increased in inflammatory states (15) , which also can increase capillary protein leakage (6, 33) . In keeping with previous reports, we noted that faster peritoneal transport and diabetes were associated with greater ECW/TBW ratios and NT-proBNP (34) . As increased NT-proBNP and ECW/TBW are associated with an increased risk for mortality (35) . This may well explain the previously reported link between PPCl and increasing co-morbidity, particularly cardiovascular and mortality (9, 12, 25, 26) . However, the ability to alter peritoneal dialysis prescriptions to adjust for volume status (35) , to transfer patients to haemodialysis with ultrafiltration failure and achieving target weights may partially explain the differences in mortality reported between studies (10, 27) .
We found no effect of residual renal function on PPCl, although residual renal protein losses appeared to be associated with a reduction in PPCl. Previous studies in PD patients have not demonstrated a strong association between ECW and residual renal function (2, 36) , although generally patients with residual renal function are less likely to be volume overloaded (37) .
There have been numerous reports linking PPCl to mortality. In some studies, this has been reported only to be with PPCl measured during the 4-h PET, others only found an association with 24-h dialysate collections, and other studies reporting no increased risk with PPCl. In view of the differences between reports we reviewed the results of PPCl obtained in a larger cohort of PD patients initiating dialysis, compared to previous studies. As expected we found that that PPCl was dependent upon dwell time and peritoneal transport status, with greater clearances with longer dwell times and faster peritoneal transporter status, and similarly greater peritoneal protein clearance was linked to greater peritoneal creatinine clearance. However, PPCl was not associated with gender, or body mass index, or primary renal disease, but was greater for those patients with increased ECW/TBW ratios and NTproBNP, suggesting an association with ECW expansion. As PPCl was also increased in those patients with greater estimated dietary protein intake and skeletal muscle mass, this would suggest a possible association with greater energy expenditure (38) , and greater sodium intake. Increased sodium balance would link ECW expansion, increased NT-proBNP and increased conduit arterial stiffness and transcapillary protein transport by hydrostatic pressure (29, 33) . As such our findings show that choice of peritoneal dialysis modality, peritoneal dialysis creatinine clearance and peritoneal transporter status determine peritoneal protein losses. In addition, PPCl is greater in patients with ECW expansion, and increased NT-proBNP accounting for previous reports linking PPCl to patient mortality.
